Lack of KRAS, NRAS, BRAF and TP53 mutations improves outcome of elderly metastatic colorectal cancer patients treated with cetuximab, oxaliplatin and UFT. [electronic resource]
Producer: 20150207Description: 155-62 p. digitalISSN:- 1776-260X
- Adenocarcinoma -- drug therapy
- Aged
- Aged, 80 and over
- Antibodies, Monoclonal, Humanized -- administration & dosage
- Antineoplastic Combined Chemotherapy Protocols -- administration & dosage
- Biomarkers, Tumor -- genetics
- Cetuximab
- Colorectal Neoplasms -- drug therapy
- DNA Mutational Analysis
- Disease-Free Survival
- Drug Resistance, Neoplasm -- genetics
- Female
- GTP Phosphohydrolases -- genetics
- Humans
- Kaplan-Meier Estimate
- Male
- Membrane Proteins -- genetics
- Mutation
- Nuclear Proteins -- genetics
- Organoplatinum Compounds -- administration & dosage
- Oxaliplatin
- Proto-Oncogene Proteins -- genetics
- Proto-Oncogene Proteins B-raf -- genetics
- Proto-Oncogene Proteins p21(ras)
- Reverse Transcriptase Polymerase Chain Reaction
- Tegafur -- administration & dosage
- Transcription Factors -- genetics
- Tumor Suppressor Protein p53 -- genetics
- Uracil -- administration & dosage
- ras Proteins -- genetics
No physical items for this record
Publication Type: Clinical Trial, Phase II; Journal Article; Multicenter Study
There are no comments on this title.
Log in to your account to post a comment.